» Articles » PMID: 37232495

Chemo-proteomics in Antimalarial Target Identification and Engagement

Overview
Journal Med Res Rev
Publisher Wiley
Date 2023 May 26
PMID 37232495
Authors
Affiliations
Soon will be listed here.
Abstract

Humans have lived in tenuous battle with malaria over millennia. Today, while much of the world is free of the disease, areas of South America, Asia, and Africa still wage this war with substantial impacts on their social and economic development. The threat of widespread resistance to all currently available antimalarial therapies continues to raise concern. Therefore, it is imperative that novel antimalarial chemotypes be developed to populate the pipeline going forward. Phenotypic screening has been responsible for the majority of the new chemotypes emerging in the past few decades. However, this can result in limited information on the molecular target of these compounds which may serve as an unknown variable complicating their progression into clinical development. Target identification and validation is a process that incorporates techniques from a range of different disciplines. Chemical biology and more specifically chemo-proteomics have been heavily utilized for this purpose. This review provides an in-depth summary of the application of chemo-proteomics in antimalarial development. Here we focus particularly on the methodology, practicalities, merits, and limitations of designing these experiments. Together this provides learnings on the future use of chemo-proteomics in antimalarial development.

Citing Articles

Eliminating malaria transmission requires targeting immature and mature gametocytes through lipoidal uptake of antimalarials.

Naude M, van Heerden A, Reader J, van der Watt M, Niemand J, Joubert D Nat Commun. 2024; 15(1):9896.

PMID: 39548094 PMC: 11568134. DOI: 10.1038/s41467-024-54144-x.


Leveraging the Aggregated Protein Dye YAT2150 for Malaria Chemotherapy.

Camarero-Hoyos C, Bouzon-Arnaiz I, Avalos-Padilla Y, Fallica A, Roman-Alamo L, Ramirez M Pharmaceutics. 2024; 16(10).

PMID: 39458619 PMC: 11514582. DOI: 10.3390/pharmaceutics16101290.


Investigating Antiprotozoal Chemotherapies with Novel Proteomic Tools-Chances and Limitations: A Critical Review.

Muller J, Boubaker G, Muller N, Uldry A, Braga-Lagache S, Heller M Int J Mol Sci. 2024; 25(13).

PMID: 39000012 PMC: 11241152. DOI: 10.3390/ijms25136903.


Chemoproteomics validates selective targeting of M1 alanyl aminopeptidase as an antimalarial strategy.

Giannangelo C, Challis M, Siddiqui G, Edgar R, Malcolm T, Webb C Elife. 2024; 13.

PMID: 38976500 PMC: 11230628. DOI: 10.7554/eLife.92990.


Novel Furopyridine and Furopyrimidine Compounds as PI4K Inhibitors for Treating Malaria and Viral Infection.

Sabnis R ACS Med Chem Lett. 2024; 15(6):779-780.

PMID: 38894915 PMC: 11181511. DOI: 10.1021/acsmedchemlett.4c00229.


References
1.
Dorman G, Prestwich G . Benzophenone photophores in biochemistry. Biochemistry. 1994; 33(19):5661-73. DOI: 10.1021/bi00185a001. View

2.
Franken H, Mathieson T, Childs D, Sweetman G, Werner T, Togel I . Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat Protoc. 2015; 10(10):1567-93. DOI: 10.1038/nprot.2015.101. View

3.
Ziegler S, Pries V, Hedberg C, Waldmann H . Target identification for small bioactive molecules: finding the needle in the haystack. Angew Chem Int Ed Engl. 2013; 52(10):2744-92. DOI: 10.1002/anie.201208749. View

4.
Younis Y, Douelle F, Feng T, Gonzalez Cabrera D, Le Manach C, Nchinda A . 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J Med Chem. 2012; 55(7):3479-87. DOI: 10.1021/jm3001373. View

5.
Terai T, Maki E, Sugiyama S, Takahashi Y, Matsumura H, Mori Y . Rational development of caged-biotin protein-labeling agents and some applications in live cells. Chem Biol. 2011; 18(10):1261-72. DOI: 10.1016/j.chembiol.2011.09.007. View